| Literature DB >> 29520391 |
Kyoung Lee1, Jae Min Chung1,2, Sang Don Lee1,2.
Abstract
Purpose: Local anesthetic agents such as bupivacaine and lidocaine are commonly used after surgery for pain control. The aim of this prospective study was to evaluate the safety of a mixture of bupivacaine and lidocaine in children who underwent urologic inguinal and scrotal surgery. Materials andEntities:
Keywords: Anesthesia, local; Bupivacaine; Lidocaine; Safety
Mesh:
Substances:
Year: 2018 PMID: 29520391 PMCID: PMC5840119 DOI: 10.4111/icu.2018.59.2.141
Source DB: PubMed Journal: Investig Clin Urol ISSN: 2466-0493
Patients' characteristics
| Characteristic | All | Group I (0–2 y) | Group II (3–4 y) | Group III (≥5 y) |
|---|---|---|---|---|
| No. of patients | 55 | 26 | 16 | 13 |
| Mean age (mo) | 40.5±39.9 | 11.9±4.5 | 39.8±12.1 | 98.5±39.0 |
| Diagnosis | ||||
| Hydrocele | 19 | 5 | 8 | 6 |
| Inguinal hernia | 6 | 1 | 3 | 2 |
| Cryptorchidism | 29 | 20 | 4 | 5 |
| Retractile testis | 1 | 0 | 1 | 0 |
| Laterality | ||||
| Unilateral | 43 | 20 | 11 | 12 |
| Bilateral | 12 | 6 | 5 | 1 |
Values are presented as number only or mean±standard deviation.
Hemodynamic changes (blood pressure, pulse rate, respiration rate) between pre-injection and post-injection (30 min, 60 min)
| Pre-injection | Post-injection | p-value | |||||
|---|---|---|---|---|---|---|---|
| 30 min | 60 min | Pre-injection vs. 30 min | Pre-injection vs. 60 min | 30 min vs. 60 min | |||
| All | BP (mmHg) | 105.0±14.6 | 121.5±21.4 | 126.7±17.9 | <0.001 | <0.001 | 0.190 |
| 60.9±13.9 | 67.1±15.2 | 66.1±17.9 | 0.27 | 0.092 | 0.744 | ||
| PR (/min) | 137.3±23.7 | 142.2±28.0 | 136.4±38.7 | 0.322 | 0.887 | 0.370 | |
| RR (/min) | 21.8±3.5 | 25.0±10.4 | 26.1±11.2 | 0.30 | 0.008 | 0.609 | |
| Group I | BP (mmHg) | 104.3±14.6 | 116.8±21.7 | 125.0±23.1 | 0.019 | <0.001 | 0.194 |
| 58.4±13.4 | 63.8±15.3 | 66.3±19.1 | 0.179 | 0.087 | 0.599 | ||
| PR (/min) | 149.5±17.1 | 152.2±31.1 | 157.0±36.6 | 0.697 | 0.346 | 0.612 | |
| RR (/min) | 22.4±3.8 | 26.8±10.1 | 26.6±12.2 | 0.044 | 0.101 | 0.951 | |
| Group II | BP (mmHg) | 104.5±17.2 | 121.1±20.5 | 129.6±19.5 | 0.19 | 0.001 | 0.236 |
| 62.3±15.4 | 65.0±15.9 | 60.8±16.6 | 0.631 | 0.785 | 0.465 | ||
| PR (/min) | 138.0±19.1 | 141.6±22.5 | 131.4±29.0 | 0.627 | 0.452 | 0.273 | |
| RR (/min) | 21.6±4.0 | 24.1±13.3 | 29.0±10.7 | 0.477 | 0.014 | 0.256 | |
| Group III | BP (mmHg) | 106.9±11.7 | 131.5±19.7 | 126.7±15.6 | 0.001 | 0.001 | 0.501 |
| 64.2±12.8 | 76.4±10.7 | 72.2±16.0 | 0.015 | 0.177 | 0.436 | ||
| PR (/min) | 111.9±20.8 | 122.8±16.4 | 101.3±24.7 | 0.150 | 0.247 | 0.015 | |
| RR (/min) | 20.8±1.5 | 22.7±5.9 | 21.5±8.6 | 0.283 | 0.802 | 0.674 | |
| Unilateral | BP (mmHg) | 105.2±15.0 | 122.5±20.2 | 126.2±19.7 | <0.001 | <0.001 | 0.393 |
| 60.5±14.8 | 68.2±15.5 | 67.1±16.1 | 0.020 | 0.050 | 0.744 | ||
| PR (/min) | 134.8±22.7 | 140.3±28.8 | 136.0±41.4 | 0.329 | 0.872 | 0.575 | |
| RR (/min) | 21.6±3.0 | 24.3±9.7 | 24.8±9.8 | 0.078 | 0.044 | 0.835 | |
| Bilateral | BP (mmHg) | 104.3±13.6 | 118.0±25.7 | 128.8±23.0 | 0.118 | 0.005 | 0.293 |
| 62.4±10.1 | 63.2±13.8 | 62.4±23.7 | 0.880 | 1 | 0.925 | ||
| PR (/min) | 146.0±26.1 | 148.9±25.0 | 137.8±28.5 | 0.782 | 0.471 | 0.322 | |
| RR (/min) | 22.7±5.0 | 27.6±12.4 | 30.8±14.6 | 0.293 | 0.080 | 0.564 | |
Values are presented as mean±standard deviation.
Group I, under 2 years; group II, between 3−4 years; group III, 5 years and above; BP, blood pressure; PR, pulse rate; RR, respiration rate.
Electrocardiographic changes (PR interval, QRS interval, QT interval) between pre-injection and post-injection (30 min, 60 min)
| Pre-injection (s) | Post-injection (s) | p-value | |||||
|---|---|---|---|---|---|---|---|
| 30 min | 60 min | Pre-injection vs. 30 min | Pre-injection vs. 60 min | 30 min vs. 60 min | |||
| All | PR interval | 0.147±0.111 | 0.134±0.019 | 0.131±0.023 | 0.430 | 0.336 | 0.513 |
| QRS interval | 0.074±0.009 | 0.079±0.009 | 0.077±0.009 | 0.004 | 0.106 | 0.249 | |
| QT interval | 0.337±0.031 | 0.337±0.049 | 0.329±0.062 | 0.974 | 0.393 | 0.494 | |
| Group I | PR interval | 0.161±0.162 | 0.131±0.021 | 0.125±0.025 | 0.382 | 0.283 | 0.355 |
| QRS interval | 0.071±0.009 | 0.076±0.009 | 0.074±0.009 | 0.044 | 0.270 | 0.338 | |
| QT interval | 0.320±0.026 | 0.316±0.048 | 0.296±0.046 | 0.679 | 0.025 | 0.156 | |
| Group II | PR interval | 0.131±0.018 | 0.131±0.048 | 0.129±0.017 | 0.989 | 0.822 | 0.828 |
| QRS interval | 0.073±0.005 | 0.079±0.005 | 0.077±0.007 | 0.001 | 0.056 | 0.364 | |
| QT interval | 0.335±0.020 | 0.333±0.022 | 0.331±0.032 | 0.804 | 0.635 | 0.793 | |
| Group III | PR interval | 0.139±0.012 | 0.147±0.010 | 0.151±0.011 | 0.124 | 0.023 | 0.372 |
| QRS interval | 0.081±0.008 | 0.084±0.009 | 0.083±0.010 | 0.320 | 0.510 | 0.806 | |
| QT interval | 0.372±0.021 | 0.396±0.036 | 0.413±0.056 | 0.069 | 0.024 | 0.432 | |
| Unilateral | PR interval | 0.153±0.125 | 0.135±0.019 | 0.131±0.023 | 0.402 | 0.298 | 0.428 |
| QRS interval | 0.074±0.009 | 0.078±0.009 | 0.077±0.009 | 0.063 | 0.282 | 0.432 | |
| QT interval | 0.339±0.034 | 0.336±0.052 | 0.331±0.067 | 0.800 | 0.514 | 0.712 | |
| Bilateral | PR interval | 0.127±0.017 | 0.130±0.017 | 0.132±0.982 | 0.688 | 0.533 | 0.820 |
| QRS interval | 0.072±0.006 | 0.079±0.007 | 0.077±0.010 | 0.004 | 0.154 | 0.340 | |
| QT interval | 0.330±0.019 | 0.338±0.036 | 0.320±0.034 | 0.526 | 0.377 | 0.264 | |
Values are presented as mean±standard deviation.
Group I, under 2 years; group II, between 3−4 years; group III, 5 years and above; PR, pulse rate.